The short version of lyophilized powder fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-11. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Composition C-4 exists in the U.S. Army Hazardous Components Safety Data Sheet on sheet number 00077. Impact tests done by the U.S. military indicate composition C-4 is less sensitive than composition C-3 and is fairly insensitive. The insensitivity is attributed to using a large amount of binder in its composition. A series of shots were fired at vials containing C-4 in a test referred to as "the rifle bullet test". Only 20% of the vials burned, and none exploded. While C-4 passed the Army's bullet impact and fragment impact tests at ambient temperature, it failed the shock stimulus, sympathetic detonation and shaped charge jet tests. Additional tests were done including the "pendulum friction test", which measured a five-second explosion temperature of 263 °C to 290 °C. The minimum initiating charge required is 0.2 grams of lead azide or 0.1 grams of tetryl. The results of 100 °C heat test are: 0.13% loss in the first 48 hours, no loss in the second 48 hours, and no explosions in 100 hours. The vacuum stability test at 100 °C yields 0.2 cubic centimeters of gas in 40 hours. Composition C-4 is essentially nonhygroscopic. The shock sensitivity of C-4 is related to the size of the nitramine particles. The finer they are the better they help to absorb and suppress shock.
=== SIRSS model - combination of SIR with modelling of social stress === Dynamics of epidemics depend on how people's behavior changes in time. For example, at the beginning of the epidemic, people are ignorant and careless, then, after the outbreak of epidemics and alarm, they begin to comply with the various restrictions and the spreading of epidemics may decline. Over time, some people get tired/frustrated by the restrictions and stop following them (exhaustion), especially if the number of new cases drops down. After resting for some time, they can follow the restrictions again. But during this pause the second wave can come and become even stronger than the first one. Social dynamics should be considered. The social physics models of social stress complement the classical epidemics models.
==== Bas-relief ==== In 1978 Joe Nickell noted that the Shroud image had a three-dimensional quality and thought its creation may have involved a sculpture of some type. He advanced the hypothesis that a medieval rubbing technique was used to produce the image, and set out to demonstrate this. He noted that while wrapping a cloth around a sculpture with normal contours would result in a distorted image, Nickell believed that wrapping a cloth over a bas-relief might result in an image like the one seen on the shroud, as it would eliminate wraparound distortions. For his demonstration, Nickell wrapped a wet cloth around a bas-relief sculpture and allowed it to dry. He then applied powdered pigment rather than wet paint (to prevent it soaking into the threads). The pigment was applied with a dauber, similar to making a rubbing from a gravestone. The result was an image with dark regions and light regions convincingly arranged. In a photo essay in Popular Photography magazine, Nickell demonstrated this technique step-by-step. Other researchers later replicated this process. In 2005 the researcher Jacques di Costanzo constructed a bas-relief of a Jesus-like face and draped wet linen over it. After the linen dried, he dabbed it with a mixture of ferric oxide and gelatine. The result was an image similar to that of the face on the Shroud.
Sources: en.wikipedia.org
=== Spread === The spread of maize cultivation in the Americas was accompanied by the adoption of the nixtamalization process. Traditional and contemporary regional cuisines (including Maya cuisine, Aztec cuisine, and Mexican cuisine) included, and still include, foods based on nixtamalized maize. The process has not substantially declined in usage in the Mesoamerican region, though there has been a decline in North America. Many Native North American tribes, such as the Huron, no longer use the process. In some Mesoamerican and North American regions, dishes are still made from nixtamalized maize prepared by traditional techniques. The Hopi produce sodium carbonate from ashes of various native plants and trees. Some contemporary Maya use calcium salts in the form of ashes of burnt mussel shells or heated limestone. By 900 CE, nixtamalizing maize based foodways began to spread to the American Southeast, serving as the dietary basis for what would come to be called Mississippian culture populations. The most important nixtamalzing dish was hominy, a dish of boiled maize kernels, either ground or whole, that were nixtamalized using woodash or wood ash lye, both made from the ashes of hardwood trees. The continuation of the hominy foodway after European colonization helped reduce cases of pellagra within twentieth century Native populations. In the United States, European settlers rarely adopted the nixtamalization process, considering it unnecessary and not to their taste, though maize became a staple among the poor of the southern states.
=== Malaria === Malaria and vitamin A deficiency are both common among young children in sub-Saharan Africa. Vitamin A supplementation to children in regions where vitamin A deficiency is common has repeatedly been shown to reduce overall mortality rates, especially from measles and diarrhea. For malaria, clinical trial results are mixed, either showing that vitamin A treatment did not reduce the incidence of probable malarial fever, or else did not affect incidence, but did reduce slide-confirmed parasite density and reduced the number of fever episodes. The question was raised as to whether malaria causes vitamin A deficiency, or vitamin A deficiency contributes to the severity of malaria, or both. Researchers proposed several mechanisms by which malaria (and other infections) could contribute to vitamin A deficiency, including a fever-induced reduction in synthesis of retinal-binding protein (RBP) responsible for transporting retinol from liver to plasma and tissues, but reported finding no evidence for a transient depression or restoration of plasma RBP or retinol after a malarial infection was eliminated.
Several surgical procedures (sleep surgery) are used to treat sleep apnea, although they are normally a third line of treatment for those who reject or are not helped by CPAP treatment or dental appliances. Surgical treatment for obstructive sleep apnea needs to be individualized to address all anatomical areas of obstruction.
Sources: en.wikipedia.org
==== 2013 resignation ==== In November 2013, Lad resigned from the Karnataka cabinet following allegations relating to illegal mining involving V. S. Lad & Sons, a company associated with his family. Contemporary reports stated that the company had been accused of illegal extraction and supply/export of iron ore. Lad said he resigned to avoid embarrassment to the Congress government and described his decision as a moral one. The resignation followed scrutiny of mining activity in the Ballari region and allegations concerning the classification of the company's mining lease. Reporting at the time also noted that the Karnataka Lokayukta had raised allegations concerning the company's mining activities.
Hahn remained modest and informal all his life. His disarming frankness, unfailing kindness, good common sense, and impish humour will be remembered by his many friends all over the world. The Royal Society in London wrote in an obituary:
Group 1.7 PAH, with an estimated 0.18% prevalence, is persistent pulmonary hypertension of the newborn. This results when the circulation does not transition from fetal to newborn configuration, leaving a patent ductus arteriosus and patent foramen ovale with left to right shunting exposing the pulmonary circulation to high pressures. PAH due to persistent pulmonary hypertension of the newborn has a 7.6% mortality at 1 year. People may sometimes have PAH belonging to more than one sub-category.
Isolated hyperCKemia is a benign genetic disorder which is characterized by high levels of creatine kinase (an enzyme) in the blood, usually, levels of CK in the blood of people with this disorder are 3 to 10 times higher than average. Unlike what most people experience when their CK blood levels are high, people with this disorder don't experience any symptoms, less commonly, people with isolated hyperCKemia have microscopic muscle cell abnormalities. This condition is a type of caveolinopathy since it is associated with the CAV3 gene, in chromosome 3. Although it is asymptomatic, people with this variant of hyperCKemia have an elevated risk of suffering from malignant hyperthermia.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.